Emitents | Grindeks, AS (5299006DWR32NKWM1O86) |
Veids | Būtiski notikumi |
Valoda | EN |
Statuss | Publicēts |
Versija | |
Datums | 2016-01-04 17:09:44 |
Versijas komentārs | |
Teksts |
Riga, Latvia January 4, 2016
JSC
“Grindeks” announces it has received the statement of the company’s
Member of the Board Vadims Rabsha on his resignation from the
position of Member of the Board on his own volition starting from
January 4, 2016. “Grindeks”
is an international, vertically integrated pharmaceutical company.
Main fields of action are research, development, manufacturing and
sales of original products, generics and active pharmaceutical
ingredients. The Group of “Grindeks” consists of five subsidiary
companies in Latvia, Estonia, Russia and Slovakia as well as
representative offices in 13 countries. “Grindeks”
specializes in the heart and cardiovascular, CNS and anti-cancer
medication therapeutic groups. A range of products covers a
successful combination of original products and generics, with the
original products Mildronate® and Ftorafur® and more than 100 forms
of generics included therein. Currently “Grindeks” produces 25
active pharmaceutical ingredients. Products
of the company are exported to 60 countries and its export
comprises 94% of the total turnover. The main markets are: Russia
and other CIS countries, the Baltic States, the Netherlands,
Germany, Canada, the U.S., France, Ireland and
Japan. To
increase production capacity and develop infrastructure, since 2002
the company has accomplished many significant investment projects,
investing more than 70 million euros over the
years. Further
information:
|
Pielikumi |
|